Cargando…

2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii

BACKGROUND: Acinetobacter baumannii (AB) is known to have high rates of multidrug resistance (MDR), new treatment options are critically needed to prevent further spread and mortality. Deferiprone (DFP), a metal chelator, has been shown to induce transient growth inhibition in previous studies, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Eales, Brianna, Smith, James, Hudson, Cole, Pouya, Nazanin, Tam, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678399/
http://dx.doi.org/10.1093/ofid/ofad500.2378
_version_ 1785150352253779968
author Eales, Brianna
Smith, James
Hudson, Cole
Pouya, Nazanin
Tam, Vincent
author_facet Eales, Brianna
Smith, James
Hudson, Cole
Pouya, Nazanin
Tam, Vincent
author_sort Eales, Brianna
collection PubMed
description BACKGROUND: Acinetobacter baumannii (AB) is known to have high rates of multidrug resistance (MDR), new treatment options are critically needed to prevent further spread and mortality. Deferiprone (DFP), a metal chelator, has been shown to induce transient growth inhibition in previous studies, and this could be potentially exploited for therapeutic purposes. The objective of the study was to examine the impact of iron limitation on the in vitro and in vivo activity of ceftazidime against AB. METHODS: An MDR bloodstream isolate (AB14) recovered from a 50 years-old male patient was used. Ceftazidime (CAZ) minimal inhibitory concentration was determined by microbroth dilution in the presence of DFP. In vitro growth profiles were discerned by an automated process (BacterioScan 216Dx) tracking CFU/mL over time. Bacteria were started at a concentration of approximately 5.5 log CFU/mL in tryptic soy broth. The effect of DFP (1000μM) and CAZ (128μg/ml) on bacterial growth was studied either alone or in combination. A neutropenic pneumonia mouse model was used in which the animals were given two doses of cyclophosphamide and one dose of uranyl nitrate intraperitoneally prior to infection. For infection, anesthetized mice were inoculated with approximately 1 × 10(6) CFU (with and without DFP) via the trachea under laryngoscopic guidance. A humanized regimen consisting of three doses of CAZ over 8h was used to mimic a dose of 2g. Quantitative culture was used to ascertain the bacterial burden of lung tissue immediately and 8h post infection. RESULTS: MIC of CAZ was reduced from > 256μg/mL to 64, 32, and 1μg/mL in the presence of 500, 1000, and 1500μM of DFP respectively. A combination of subinhibitory concentrations of CAZ and DFP resulted in minimal (< 0.5 log CFU/mL) growth in 20h. The lung bacterial burden of the control groups increased ≥ 1 log CFU/g after 8h, whereas the combination group (CAZ + DFP) stayed comparable to baseline. Control groups compared to combination was statistically different p< 0.05). CONCLUSION: These results support that limiting iron has the potential to be a novel approach to treating MDR AB infections. Further research is warranted to broaden the scope to encompass additional clinical isolates, and to optimize the approach as a therapeutic solution. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10678399
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106783992023-11-27 2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii Eales, Brianna Smith, James Hudson, Cole Pouya, Nazanin Tam, Vincent Open Forum Infect Dis Abstract BACKGROUND: Acinetobacter baumannii (AB) is known to have high rates of multidrug resistance (MDR), new treatment options are critically needed to prevent further spread and mortality. Deferiprone (DFP), a metal chelator, has been shown to induce transient growth inhibition in previous studies, and this could be potentially exploited for therapeutic purposes. The objective of the study was to examine the impact of iron limitation on the in vitro and in vivo activity of ceftazidime against AB. METHODS: An MDR bloodstream isolate (AB14) recovered from a 50 years-old male patient was used. Ceftazidime (CAZ) minimal inhibitory concentration was determined by microbroth dilution in the presence of DFP. In vitro growth profiles were discerned by an automated process (BacterioScan 216Dx) tracking CFU/mL over time. Bacteria were started at a concentration of approximately 5.5 log CFU/mL in tryptic soy broth. The effect of DFP (1000μM) and CAZ (128μg/ml) on bacterial growth was studied either alone or in combination. A neutropenic pneumonia mouse model was used in which the animals were given two doses of cyclophosphamide and one dose of uranyl nitrate intraperitoneally prior to infection. For infection, anesthetized mice were inoculated with approximately 1 × 10(6) CFU (with and without DFP) via the trachea under laryngoscopic guidance. A humanized regimen consisting of three doses of CAZ over 8h was used to mimic a dose of 2g. Quantitative culture was used to ascertain the bacterial burden of lung tissue immediately and 8h post infection. RESULTS: MIC of CAZ was reduced from > 256μg/mL to 64, 32, and 1μg/mL in the presence of 500, 1000, and 1500μM of DFP respectively. A combination of subinhibitory concentrations of CAZ and DFP resulted in minimal (< 0.5 log CFU/mL) growth in 20h. The lung bacterial burden of the control groups increased ≥ 1 log CFU/g after 8h, whereas the combination group (CAZ + DFP) stayed comparable to baseline. Control groups compared to combination was statistically different p< 0.05). CONCLUSION: These results support that limiting iron has the potential to be a novel approach to treating MDR AB infections. Further research is warranted to broaden the scope to encompass additional clinical isolates, and to optimize the approach as a therapeutic solution. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678399/ http://dx.doi.org/10.1093/ofid/ofad500.2378 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Eales, Brianna
Smith, James
Hudson, Cole
Pouya, Nazanin
Tam, Vincent
2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii
title 2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii
title_full 2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii
title_fullStr 2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii
title_full_unstemmed 2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii
title_short 2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii
title_sort 2767. impact of iron limitation on in vitro and in vivo activity of ceftazidime against a. baumannii
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678399/
http://dx.doi.org/10.1093/ofid/ofad500.2378
work_keys_str_mv AT ealesbrianna 2767impactofironlimitationoninvitroandinvivoactivityofceftazidimeagainstabaumannii
AT smithjames 2767impactofironlimitationoninvitroandinvivoactivityofceftazidimeagainstabaumannii
AT hudsoncole 2767impactofironlimitationoninvitroandinvivoactivityofceftazidimeagainstabaumannii
AT pouyanazanin 2767impactofironlimitationoninvitroandinvivoactivityofceftazidimeagainstabaumannii
AT tamvincent 2767impactofironlimitationoninvitroandinvivoactivityofceftazidimeagainstabaumannii